CN108815301A - Has effects that composition of leukocytosis promoting and preparation method thereof - Google Patents
Has effects that composition of leukocytosis promoting and preparation method thereof Download PDFInfo
- Publication number
- CN108815301A CN108815301A CN201810707192.8A CN201810707192A CN108815301A CN 108815301 A CN108815301 A CN 108815301A CN 201810707192 A CN201810707192 A CN 201810707192A CN 108815301 A CN108815301 A CN 108815301A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- group
- preparation
- pawpaw
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to having effects that composition of leukocytosis promoting and preparation method thereof, bulk pharmaceutical chemicals Radix Astragali, pawpaw, Poria cocos, fructus lycii, Radix Angelicae Sinensis are mixed, 10~20 times of waters are extracted 2 times, each 2h, and extracting solution merging is condensed into paste, are dried in vacuo, are pulverized and sieved；The mixture of the donkey-hide gelatin after pulverizing and sieving and ginseng is added, royal jelly granulation is added.The effect of Chinese medicine composition that the present invention announces has apparent increasing leukocyte, improves immunity can also assist that cancer cell is inhibited to increase, and toxic side effect substantially reduces compared with the shengbai drug of listing.
Description
Technical field
The invention belongs to biological chemical fields, and in particular to a kind of to have effects that the composition of leukocytosis promoting and its system
Preparation Method.
Background technique
In recent years, Cancer Mortality significantly rises, and chemicotherapy is the postoperative common treatment of current malignant tumor patient
Scheme, but chemicotherapy is often associated with that dizzy, vomiting, out of strength, limbs are aching and limp, appetite stimulator, the symptoms such as apathetic, wherein inhibiting
Bone marrow cell growth is the toxic side effect of chemicotherapy most serious, generally has 50%~70% patient can be because there is oligoleukocythemia, very
It is also reduced to red blood cell, hemoglobin and blood platelet, so that serious infection occurs and then threatens patient vitals.Therefore, pernicious
The high partly cause of tumor mortality rate be postoperative chemotherapy it is ineffective or as leucocyte seriously reduce terminate chemicotherapy caused by.
Increasing leukocyte medicament categories are more at present, such as leucogen, batyl alcohol, but curative effect is not good enough.Recombinant humangranulocyte
Although colony stimulating factor works well, but its somewhat expensive, and often has rebound phenomenon and cause fever, Muscular stiffness etc. and is bad
Reaction, to limit its clinical application.
In recent years, scientific circles proposed " integration of drinking and medicinal herbs " concept, emphasized to reach treatment disease by improving human diet habit
Effect, traditional Chinese medicine technology just embodied its unique advantage.The cardinal symptom of " leukopenia " has out of strength, head in medicine
Dizzy, palpitaition, easy fever caused by exogenous pathogens etc. belong to the scopes such as traditional Chinese medicine " qi-blood deficiency ", " consumptive disease ", " warm disease ", " all empty insufficient ".It is modern
Pharmaceutical research thinks that the product of benefiting qi and nourishing blood have strengthen immunity, promotes hemopoietic function of bone marrow to restore, to reduce chemotherapy
Adverse reaction.Researches show that simple astragalus polyose, general ginsenoside, pachymaran, panaxan, danggui buxue decoction, it is middle at
Medicine Shuanghuang Shengbai granule etc. can significantly raised model mice leukocyte count, red blood cell number, platelet count, granulophilocyte
Number, bonemarrow nucleated cells number and content cause bone marrow suppression mouse hemopoietic system to have protective effect chemotherapy.
Summary of the invention
The object of the present invention is to provide a kind of compositions and preparation method thereof with leukocytosis promoting, can not only
Quantity of leucocyte is improved, immunity of organisms is enhanced, can also assist that cancer cell is inhibited to increase.
The technical scheme adopted by the invention is as follows：
Have effects that the composition of leukocytosis promoting, it is characterised in that：
The composition includes the component of following mass parts：
5~40 parts of Radix Astragali；
2~20 parts of pawpaw；
2~20 parts of Poria cocos；
2~20 parts of fructus lycii；
1~10 part of Radix Angelicae Sinensis；
1~12 part of ginseng；
1~15 part of donkey-hide gelatin；
1~20 part of royal jelly.
The composition includes the component of following mass parts：
35 parts of Radix Astragali；
15 parts of pawpaw；
15 parts of Poria cocos；
15 parts of fructus lycii；
7 parts of Radix Angelicae Sinensis；
8 parts of ginseng；
5 parts of donkey-hide gelatin；
15 parts of royal jelly.
Have effects that the preparation method of the composition of leukocytosis promoting as mentioned, it is characterised in that：
Bulk pharmaceutical chemicals Radix Astragali, pawpaw, Poria cocos, fructus lycii, Radix Angelicae Sinensis are mixed, 10~20 times of waters are extracted 2 times, each 2h, and extracting solution closes
And it is condensed into paste, it is dried in vacuo, pulverizes and sieves；
The mixture of the donkey-hide gelatin after pulverizing and sieving and ginseng is added, royal jelly granulation is added.
It extracts and uses reflowing mode.
C after granulation60Irradiation.
Granule, tablet, capsule, pill, powder or decoction are made after granulation.
The present invention has the following advantages that：
The present invention in line with strengthening the spleen and replenishing qi, kidney tonifying, nourishing yin and supplementing blood therapeutic purposes, several kinds of Chinese medicinal materials is screened, is therefrom selected
The crude drugs such as Radix Astragali, pawpaw, Poria cocos, fructus lycii, Radix Angelicae Sinensis, ginseng, donkey-hide gelatin, royal jelly, effect are as follows：
Radix Astragali：It is sweet in flavor, return lung, the spleen channel.Major function is strengthening the spleen and replenishing qi, and benefiting qi and nourishing blood is used for deficiency of vital energy and acking in strength, exterior deficiency spontaneous perspiration, gas
Empty oedema.Astragalus polyose is the effective ingredient for enhancing phagocyte phagocytic function.
Radix Angelicae Sinensis：Promoting blood circulation, research shows that itself and Radix Astragali 1：5 are used cooperatively, and function of increasing leukocyte is best, promote marrow
The proliferation of cell inhibits Apoptosis in Marrow Cells.
Pawpaw：Pawpaw contains carrotene and vitamin C abundant, they have very strong oxidation resistance, and enhancing human body is exempted from
Epidemic disease power helps body to resist the virus attack including Flu-A.Effective component in pawpaw fruit, which has, increases phagocytosis
The effect of cell.
Fructus lycii：For consumption consumptive loss, dizziness and tinnitus, Heat Diabetes, blood deficiency chlorosis.With immunoregulation effect；It can be improved
Plasma testosterone level；There is facilitation to hematopoiesis function；Also there is significant function of increasing leukocyte to normal healthy people.
Poria cocos：For edema and little urine, phlegm retention anti-dazzle nervous, spleen eating less, loose stool diarrhea.It is dynamic that research finds that pachymaran can be improved
Object the phagocytosis ratio and phagocytosis index of macrophage, enhances T cell toxicity, and enhancing animal cell immunity reaction promotes mouse spleen
NK cell activity.
Ginseng：Main component ginsenoside have antitumor, strengthen immunity function, panaxan to specific immunity with
Nospecific immunity, cellular immunity and humoral immunity all have an impact.
Donkey-hide gelatin：It enriches blood enriching yin, moisturizes, stop blooding.For blood deficiency chlorosis, dizziness palpitaition.
Royal jelly：Reinforce Abwehrkraft des Koepers, takes orally or inject the blood red of the diameter and granulophilocyte that can increase red blood cell
Albumen, blood iron content dramatically increases, and increases number of platelets.
Specific embodiment
The present invention will be described in detail With reference to embodiment.
Have effects that the composition of leukocytosis promoting the present invention relates to a kind of, includes the component of following mass parts：
5~40 parts of Radix Astragali；
2~20 parts of pawpaw；
2~20 parts of Poria cocos；
2~20 parts of fructus lycii；
1~10 part of Radix Angelicae Sinensis；
1~12 part of ginseng；
1~15 part of donkey-hide gelatin；
1~20 part of royal jelly.
Preferably, the composition includes the component of following mass parts：
35 parts of Radix Astragali；
15 parts of pawpaw；
15 parts of Poria cocos；
15 parts of fructus lycii；
7 parts of Radix Angelicae Sinensis；
8 parts of ginseng；
5 parts of donkey-hide gelatin；
15 parts of royal jelly.
The above-mentioned preparation method with the composition of leukocytosis promoting is, by bulk pharmaceutical chemicals Radix Astragali, pawpaw, Poria cocos,
Fructus lycii, Radix Angelicae Sinensis mixing, 10~20 times of waters are extracted 2 times, each 2h, and extracting solution merging is condensed into paste, are dried in vacuo, be crushed
Sieve；The mixture of the donkey-hide gelatin after pulverizing and sieving and ginseng is added, royal jelly granulation is added.It extracts and uses reflowing mode.System
C after grain60Irradiation.
Composition can be made into granule, tablet, capsule, pill, powder or decoction etc..
Embodiment 1 weighs raw material according to formula as below composition：30 parts of Radix Astragali, 20 parts of pawpaw, 15 parts of Poria cocos, fructus lycii 15
Part, 7 parts of Radix Angelicae Sinensis, 10 parts of ginseng, 5 parts of donkey-hide gelatin, 12 parts of royal jelly.Radix Astragali, pawpaw, Poria cocos, fructus lycii, Radix Angelicae Sinensis are proportionally added into 10 times
Water depressurizes 100 DEG C and extracts 2 times, each 2h, and combined extract is concentrated into paste, and ginseng pulverate, gelatin powder, appropriate queen bee is added
Slurry mixes and crushes granulation.Pour into capsule, every 0.4g.
Embodiment 2 forms according to formula as below and weighs bulk pharmaceutical chemicals, and 35 parts of Radix Astragali, 15 parts of pawpaw, 15 parts of Poria cocos, fructus lycii 15
Part, 7 parts of Radix Angelicae Sinensis, 8 parts of ginseng, 5 parts of donkey-hide gelatin, 15 parts of royal jelly.Radix Astragali, pawpaw, Poria cocos, fructus lycii, Radix Angelicae Sinensis are proportionally added into 10 times
Water depressurizes 100 DEG C and extracts 2 times, each 2h, and combined extract is concentrated into paste, and ginseng pulverate, gelatin powder, appropriate queen bee is added
Slurry mixes and crushes granulation.Pour into capsule, every 0.4g.
Embodiment 3 forms according to formula as below and weighs bulk pharmaceutical chemicals, and 35 parts of Radix Astragali, 15 parts of pawpaw, 15 parts of Poria cocos, fructus lycii 20
Part, 10 parts of Radix Angelicae Sinensis, 10 parts of ginseng, 3 parts of donkey-hide gelatin, 15 parts of royal jelly.Radix Astragali, pawpaw, Poria cocos, fructus lycii, Radix Angelicae Sinensis are proportionally added into 10
Times water depressurizes 100 DEG C and extracts 2 times, each 2h, and combined extract is concentrated into paste, and ginseng pulverate, gelatin powder, appropriate bee is added
Royal jelly and a certain amount of auxiliary material are mixed and are crushed, wet granule compression tablet, every 0.4g.
4 increasing leukocyte composition of embodiment is to SD rat therapeutic effect
The common SD rat of 1.1 modellings（Male, weight 200g or so, the monthly age 3~4 months）60, according to weight, basis
Total white blood cells are divided into 6 groups（Blank group, model group, positive controls, example 1 group close object, 2 composition of embodiment, reality
Apply 3 composition of example）, every group 10.SD rats by intraperitoneal injection cyclophosphamide 25mg/kg, 1 time/d, continuous 5 days.The 5th after modeling
Its 25mg/kg cyclophosphamide booster shots 1 time.The metering physiological saline such as blank group intraperitoneal injection, method are same as above.
1.2 gastric infusion each group gastric infusions, Examples 1 to 3 dosage are 30mg/100g/d, positive drug group shark liver
Alcohol dosage is 10mg/100g/d, and blank group and model group inject isometric physiological saline respectively.It was administered from modeling the 7th day,
Successive administration 14 days.
1.3 testing indexs measure each test group, positive controls, model group, blank control group the weight of animals, peripheral blood
Leucocyte, each organ weights.
Experimental result：As shown in table 1, the increasing leukocyte composition that prepared by the embodiment of the present invention 1~3 can increase leucocyte
The weight of low rat increases the peripheral leukocytes of rat, and does not have toxic side effect to each internal organs, and embodiment 2 increases
The effect of leucocyte is best.
5 animal experiment in vivo of embodiment
1 experimental method and step
1.1 model production methods are same as Example 4.
1.2 gastric infusion each group gastric infusion embodiment, 2 composition, low dose group 15.1mg/100g/d, middle dose group
30.2mg/100g/d, high dose group 60.4mg/100g/d, positive drug group batyl alcohol 10mg/100g/d, blank group and model group
Isometric physiological saline is injected respectively.It was administered from modeling the 7th day, successive administration 14 days.
1.3 observation index and the daily observation general upgrowth situation of rat of detection, such as spirit, activity, hair, stool, point
1 day not after modeling the last week, modeling, weigh rat body weight within 7 days, 14 days, 21 days, rat eye socket takes blood, cellanalyzer
Count peripheral white blood cells（WBC）, administration last day, which dislocates, puts to death, and broken abdomen wins thymus gland, spleen, weighs each organ mass,
Calculate spleen, thymus index.
2 results of animal
2.1 weight
As the result is shown：Each group rat body weight 200g or so before modeling, there was no significant difference（?P>0.05）, have between group comparable
Property；The 1st day after modeling, weight slightly rises, and due to Toxicity of Cyclophosphamide intervention, weight is declined within the 7th day, the 14th after modeling
Rise state is presented in its positive controls, experimental group weight.
2.2 peripheral white blood cells
As the result is shown：Quantity of leucocyte is stablized on the day of modeling the last week and modeling, and modeling detects after seven days, in addition to blank group,
Remaining group quantity of leucocyte is reduced to 2 × 109Left and right illustrates modeling success, is administered the 7th day（14 days after modeling）Positive control
Group and middle and high dosage group have obvious rising, and high dose group has reached normal level, are administered the 14th day（21 days after modeling）, remove mould
Type group, remaining each group leukocyte count rebound significantly, positive controls and high dose group reach normal level.In conclusion group
The duration of leukopenia can be shortened by closing object, quantity of leucocyte be substantially improved, high dose group experimental result is substantially better than
Positive controls.
2.3 immune organ quality and index
Spleen and thymic factor D injection, the index of model group are below blank group, illustrate that cyclophosphamide has the immune organ of rat
Damaging action.Various dose group is improved with dosage, and spleen and thymic factor D injection, index are all increasing, and illustrates rat to medicine group
Closing object has certain pharmacological dependence relationship, and the indices of high dose group are substantially better than positive controls.
6 increasing leukocyte composition of embodiment assists rising white test in the low volunteer of leucocyte
1. data and method
1.1 object case sources are selected from June, 2015 to the lung cancer of diagnosis and treatment in June, 2017, gastric cancer, colon cancer, breast cancer etc.
200 patients undergoing chemotherapies, are diagnosed as malignant tumour through cytology or histopathology, check that surrounding hemogram confirms after chemotherapy
Total white blood cells are consistently less than 4 × 109/ L through patient hereinafter, agree to take this composite preparation, and can complete whole chemotherapy.
（Exclude following patient：Other any shengbai drug persons, severe cardiac, liver, kidney, disease in the blood system patient, sense are applied during chemotherapy
Dye patient and gestational patients have drug and food hypersenstivity history person.）.In addition taking object further includes 60 normal health crowds.It will
Patient is grouped by gender, average age, disease, pain degree scoring.Treatment group 1：Male 35, female 33, average year
Age 51.7 years old, take 2 composition of middle dosage embodiment；Treatment group 2：It male 33, female 32, average age 53.3 years old, takes
2 composition of high dose group embodiment；Positive controls 3：Male 32, average age 52.8 years old, takes positive drug shark liver by female 35
Alcohol；Other 60 Healthy People groups 4：Male 30, average age 53 years old, takes middle dosage composition by female 30.
The distribution of 1.2 leucocytes
According to the World Health Organization（WHO）Defined indexing standard：
0 degree：WBC, which is counted, is not less than 4 × 109/ L, WBC are not reduced；
I degree：WBC counts 3.0 × 109/ L~3.9 × 109/ L, it is slight to reduce；
II degree：WBC counts 2.0 × 109/ L~2.9 × 109/ L, moderate reduce；
III degree：WBC counts 1.0 × 109/ L~1.9 × 109/ L, severe reduce；
IV degree：WBC, which is counted, is lower than 1.0 × 109/ L, only a few patient understand threat to life.
1.3 treatment method
The capsule of the preparation of the embodiment of the present invention 2 is given by treatment group 1.It is taken orally after 24 h of end of chemotherapy, 3 times a day, often
Secondary 2.The course for the treatment of is 14 days；
The capsule of the preparation of the embodiment of the present invention 2 is given by treatment group 2.It is taken orally after 24 h of end of chemotherapy, 3 times a day, often
Secondary 4.The course for the treatment of is 14 days；
Positive controls 3 give soft-shelled turtle liver alcohol piece, after 24 h of end of chemotherapy take orally, 3 times a day, each 50mg；
The capsule of the preparation of the embodiment of the present invention 2 is given by Healthy People group 4.3 times a day, 1 tablet each time.The course for the treatment of is 14 days；
All patients use the chemotherapy regimen of corresponding illness, extract patient's empty stomach ulnar vein blood in early morning before and after treatment with routine
Detection counts, and also blood drawing detects routine blood indexes in the morning for Healthy People group, compares each group patient's situation of change.
2. experimental result
It is as shown in the table that the pretherapy and post-treatment WBC of each group counts situation：
Treat first three groups patient（Treatment group 1, treatment group 2, positive controls 3）Counting compare, there is no statistics meanings for difference
Justice, three groups of patients after treatment（Treatment group 1, treatment group 2, positive controls 3）Compared with pre-treatment, difference exists quantity of leucocyte
Statistical significance, and reach normal person's value, wherein 2 effect for the treatment of group is the most obvious；After healthy population is taken, to leukocyte count
Measure no significant changes.
The pretherapy and post-treatment WBC distribution situation of each group is as shown in the table：
The patient for reaching normal white cell number in treatment group 1 accounts for the 78% of this group of patient, and normal white cell number is reached in treatment group 2
Patient account for the 85% of this group of patient, the patient that normal white cell number is reached in positive controls accounts for the 80.6% of this group of patient.It controls
There is not adverse reaction in the patient for the treatment of group 1,2, has 30 patients to occur in positive controls out of strength, loss of appetite, spirit is withered
It wastes, katzeniammer, the symptoms such as vomiting.
In conclusion the effect of Chinese medicine composition that the present invention announces has apparent increasing leukocyte, improves immunity,
Toxic side effect substantially reduces compared with the shengbai drug of listing simultaneously.
The contents of the present invention are not limited to cited by embodiment, and those of ordinary skill in the art are by reading description of the invention
And to any equivalent transformation that technical solution of the present invention is taken, all are covered by the claims of the invention.
Claims (6)
1. having effects that the composition of leukocytosis promoting, it is characterised in that：
The composition includes the component of following mass parts：
5~40 parts of Radix Astragali；
2~20 parts of pawpaw；
2~20 parts of Poria cocos；
2~20 parts of fructus lycii；
1~10 part of Radix Angelicae Sinensis；
1~12 part of ginseng；
1~15 part of donkey-hide gelatin；
1~20 part of royal jelly.
2. according to claim 1 have effects that the composition of leukocytosis promoting, it is characterised in that：
The composition includes the component of following mass parts：
35 parts of Radix Astragali；
15 parts of pawpaw；
15 parts of Poria cocos；
15 parts of fructus lycii；
7 parts of Radix Angelicae Sinensis；
8 parts of ginseng；
5 parts of donkey-hide gelatin；
15 parts of royal jelly.
3. having effects that the preparation method of the composition of leukocytosis promoting as described in claim 1, it is characterised in that：
Bulk pharmaceutical chemicals Radix Astragali, pawpaw, Poria cocos, fructus lycii, Radix Angelicae Sinensis are mixed, 10~20 times of waters are extracted 2 times, each 2h, and extracting solution closes
And it is condensed into paste, it is dried in vacuo, pulverizes and sieves；
The mixture of the donkey-hide gelatin after pulverizing and sieving and ginseng is added, royal jelly granulation is added.
4. the preparation method with the composition of leukocytosis promoting according to claim 3, it is characterised in that：
It extracts and uses reflowing mode.
5. the preparation method with the composition of leukocytosis promoting according to claim 3, it is characterised in that：
C after granulation60Irradiation.
6. the preparation method with the composition of leukocytosis promoting according to claim 3, it is characterised in that：
Granule, tablet, capsule, pill, powder or decoction are made after granulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810707192.8A CN108815301A (en) | 2018-07-02 | 2018-07-02 | Has effects that composition of leukocytosis promoting and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810707192.8A CN108815301A (en) | 2018-07-02 | 2018-07-02 | Has effects that composition of leukocytosis promoting and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108815301A true CN108815301A (en) | 2018-11-16 |
Family
ID=64134150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810707192.8A Pending CN108815301A (en) | 2018-07-02 | 2018-07-02 | Has effects that composition of leukocytosis promoting and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108815301A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109432226A (en) * | 2018-07-04 | 2019-03-08 | 西安巨子生物基因技术股份有限公司 | It is a kind of to have effects that the composition of leukocytosis promoting |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306848A (en) * | 2000-01-26 | 2001-08-08 | 中国石化集团齐鲁石油化工公司 | Chinese medicine preparation for preventing and treating leucocytopenia and its preparation process |
| US20150265664A1 (en) * | 2012-09-13 | 2015-09-24 | Jiangzhong Pharmaceutical Co., Ltd. | Traditional chinese medicine combination for regulating immune function and preparation method therefor |
| CN105521100A (en) * | 2016-01-26 | 2016-04-27 | 青岛华之草医药科技有限公司 | Traditional Chinese medicinal composition for treating leucopenia after chemotherapy |
| CN105616633A (en) * | 2016-01-26 | 2016-06-01 | 青岛华之草医药科技有限公司 | Preparation method of traditional Chinese medicine composition for treating leukopenia after chemotherapy |
-
2018
- 2018-07-02 CN CN201810707192.8A patent/CN108815301A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306848A (en) * | 2000-01-26 | 2001-08-08 | 中国石化集团齐鲁石油化工公司 | Chinese medicine preparation for preventing and treating leucocytopenia and its preparation process |
| US20150265664A1 (en) * | 2012-09-13 | 2015-09-24 | Jiangzhong Pharmaceutical Co., Ltd. | Traditional chinese medicine combination for regulating immune function and preparation method therefor |
| CN105521100A (en) * | 2016-01-26 | 2016-04-27 | 青岛华之草医药科技有限公司 | Traditional Chinese medicinal composition for treating leucopenia after chemotherapy |
| CN105616633A (en) * | 2016-01-26 | 2016-06-01 | 青岛华之草医药科技有限公司 | Preparation method of traditional Chinese medicine composition for treating leukopenia after chemotherapy |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109432226A (en) * | 2018-07-04 | 2019-03-08 | 西安巨子生物基因技术股份有限公司 | It is a kind of to have effects that the composition of leukocytosis promoting |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632819B (en) | Preparation for resisting suppression of bone marrow after lung cancer chemotherapy | |
| CN102772671B (en) | Traditional Chinese medicine composition for treating deficiency of both qi and yin of sicca syndrome | |
| CN102600212B (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN106390013B (en) | It is a kind of inhibit colorectal cancer hepatic metastases compound traditional Chinese medicine composite preparation method and application | |
| CN103053908B (en) | Functional food capable of rising white blood cells and preparation method thereof | |
| CN103156122B (en) | Health-care Astragalus mongholicus porridge and preparation method thereof | |
| CN103386078B (en) | A kind of Chinese medicine composition is preparing the application in treating colon cancer drug | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN104855734A (en) | Assisted dog food for fat dogs and preparation method of assisted dog food | |
| CN102078511A (en) | Medicine for promoting leukopoiesis | |
| CN102048902B (en) | Hepatitis treating traditional Chinese medicine composition, extract and preparation method, application and formulation | |
| CN108815301A (en) | Has effects that composition of leukocytosis promoting and preparation method thereof | |
| CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
| CN105535285A (en) | Chinese herbal preparation with antitumor effect and preparation method and application thereof | |
| CN102631518B (en) | New medicament for treating leukemia | |
| CN102028924A (en) | Medicinal composition for late gastric cancer | |
| CN101732484A (en) | Capsule for restoring vital energy and producing blood | |
| CN104491810A (en) | Traditional Chinese medicine for treating syndromes of acquired immunodeficiency syndrome of deficiency of qi and blood and damp-heat wind pathogen | |
| CN104524292A (en) | Application of traditional Chinese medicine preparation in preparation of medicament for treating obesity | |
| CN105168887B (en) | Kidney-tonifying and vitality-nourishing soft capsule and preparation process thereof | |
| CN103417799A (en) | Applications of a traditional Chinese medicine composition in preparing medicines treating anaemia | |
| CN109432226A (en) | It is a kind of to have effects that the composition of leukocytosis promoting | |
| CN106511915A (en) | Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis | |
| CN106581633A (en) | Lucid ganoderma oral liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181116 |
|
| RJ01 | Rejection of invention patent application after publication |